SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits |
| |
| Authors: | Giovanna Leoncini Elisa Russo Elisabetta Bussalino Cecilia Barnini Francesca Viazzi Roberto Pontremoli |
| |
| Affiliation: | Department of Internal Medicine, the University of Genoa and IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy; (G.L.); (E.R.); (E.B.); (C.B.); (F.V.) |
| |
| Abstract: | In recent years, following the publication of results from several RCTs, first on cardiovascular and more recently on renal outcomes, SGLT2is have become the standard of care to prevent diabetic kidney disease and slow its progression. This narrative review focuses on biological mechanisms, both renal and extrarenal, underlying kidney protection with SGLT2is. Furthermore, data from cardiovascular as well as renal outcome trials, mostly conducted in diabetic patients, are presented and discussed to provide an overview of current uses as well as the future therapeutic potential of these drugs. |
| |
| Keywords: | SGLT2 inhibitors kidney protection kidney disease |
|
|
